Viridian reports Q2 2026 results as Lumvoa launch begins in the U.S.
The FDA-approved thyroid eye disease drug started shipping doses in July, while Viridian keeps a Q1 2027 BLA target for follow-on candidate elegrobart.
Viridian Therapeutics reported second quarter 2026 results on August 6, 2026, covering the period ended June 30, 2026. The FDA approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease on June 26, 2026.1
As of July 31, 2026, the company said its field sales team had engaged with 95% of the 2,000 core prescribing physicians, with strong and positive early feedback.1 The company reported that initial doses of Lumvoa began going to patients in July, with early enrollment activity pointing to broad physician interest.1 Viridian also activated ViridianCares, its patient support program, at the time of approval to help patients and providers navigate insurance coverage.1
On the pipeline side, Viridian said it remains on track to submit a Biologics License Application for elegrobart in the first quarter of 2027.1 The company reported positive topline results from the REVEAL-1 and REVEAL-2 phase 3 trials of subcutaneous elegrobart in active and chronic TED, respectively, with both Q4W and Q8W dosing showing reductions in proptosis at week 24, Q4W additionally showing benefit on diplopia, and a safety profile the company described as consistent with the anti-IGF-1R drug class.1
For the FcRn portfolio, Viridian said its VRDN-008 phase 1 healthy volunteer trial is ongoing, with data still expected in the second half of 2026.1 The company also reported that VRDN-006 showed IgG reductions consistent with the FcRn inhibitor class in a phase 1 trial, and said it plans to share development plans for that program in 2026.1 Separately, Viridian said it plans to file an IND for its TSHR antibody program in the fourth quarter of 2026.1
On financing, cash, cash equivalents, and marketable securities totaled $981.5 million as of June 30, 2026, up from $762.2 million at the end of the first quarter.1 The company said its current cash along with anticipated commercial revenue from Lumvoa and, if approved, elegrobart is intended to support its operating plans through profitability.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.